The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Response Genetics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Response Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Response Genetics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
Response
Response Genetics Relative Risk vs. Return Landscape
If you would invest 0.01 in Response Genetics on October 29, 2025 and sell it today you would earn a total of 0.00 from holding Response Genetics or generate 0.0% return on investment over 90 days. Response Genetics is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Response, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
Expected Return
Risk
Response Genetics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Response Genetics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Response Genetics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Response Genetics generated a negative expected return over the last 90 days
Response Genetics has some characteristics of a very speculative penny stock
Response Genetics has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 18.04 M. Net Loss for the year was (20.18 M) with profit before overhead, payroll, taxes, and interest of 6.23 M.
Response Genetics has accumulated about 1.73 M in cash with (13.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Response Genetics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Response Pink Sheet often depends not only on the future outlook of the current and potential Response Genetics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Response Genetics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding
38.8 M
Cash And Short Term Investments
19.5 M
Response Genetics Fundamentals Growth
Response Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Response Genetics, and Response Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Response Pink Sheet performance.
Assessing Response Genetics' fundamental ratios provides investors with valuable insights into Response Genetics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Response Genetics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. RESPONSE GENETICS operates under Diagnostics Research classification in the United States and is traded on PNK Exchange. It employs 96 people.
Things to note about Response Genetics performance evaluation
Checking the ongoing alerts about Response Genetics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Response Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Response Genetics generated a negative expected return over the last 90 days
Response Genetics has some characteristics of a very speculative penny stock
Response Genetics has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 18.04 M. Net Loss for the year was (20.18 M) with profit before overhead, payroll, taxes, and interest of 6.23 M.
Response Genetics has accumulated about 1.73 M in cash with (13.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Response Genetics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Response Genetics' pink sheet performance include:
Analyzing Response Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Response Genetics' stock is overvalued or undervalued compared to its peers.
Examining Response Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Response Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Response Genetics' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Response Genetics' pink sheet. These opinions can provide insight into Response Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Response Genetics' pink sheet performance is not an exact science, and many factors can impact Response Genetics' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Response Pink Sheet Analysis
When running Response Genetics' price analysis, check to measure Response Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Response Genetics is operating at the current time. Most of Response Genetics' value examination focuses on studying past and present price action to predict the probability of Response Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Response Genetics' price. Additionally, you may evaluate how the addition of Response Genetics to your portfolios can decrease your overall portfolio volatility.